Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SelectiveTGFb-inhib

Financiado

Pro tumorigenic effects of TGFb elucidation of mechanisms and development of s...

Pro tumorigenic effects of TGFb elucidation of mechanisms and development of selective inhibitors Transforming growth factor-b (TGFb) is a multifunctional cytokine which has important functions during embryonal development and in tissue homeostasis. In cancer, TGFb is often overexpressed and has both tumor suppressor effects (... ver más

31/10/2023

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-10-31

ERC-2017-ADG: ERC Advanced Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

2.50M€ | Lider

LABORATORIO DE INVESTIGACION...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-20859 BASES MOLECULARES DEL EFECTO PRO-ANGIOGENICO DEL TGFBETA EN... 194K€ Cerrado

SAF2013-46183-R FUNCION DE LAS GLICOPROTEINAS DE LA SUPERFICIE CELULAR PODOP... 254K€ Cerrado

PDC2021-121226-I00 UN NUEVO INHIBIDOR DEL RECEPTOR TIPO 1 (ALK5) DEL TGF-BETA;... 150K€ Cerrado

SAF2009-11757 CARACTERIZACION DE GENES ESTROMALES PROMOTORES DE LA PROGRES... 36K€ Cerrado

SAF2013-48849-C2-1-R TRANSICION EPITELIO-MESENQUIMA Y DESARROLLO TUMORAL: ANALISI... 472K€ Cerrado

BES-2011-048120 BASES MOLECULARES DEL EFECTO PRO-ANGIOGENICO DEL TGFBETA EN... 43K€ Cerrado

Duración del proyecto: 64 meses Fecha Inicio: 2018-06-20
Fecha Fin: 2023-10-31

Líder del proyecto

UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Transforming growth factor-b (TGFb) is a multifunctional cytokine which has important functions during embryonal development and in tissue homeostasis. In cancer, TGFb is often overexpressed and has both tumor suppressor effects (induction of growth arrest and apoptosis) and tumor promoting effects (stimulation of epithelial-mesenchymal transition (EMT) of tumor cells, stimulation of angiogenesis and cancer associated fibroblasts, and suppression of immune surveillance). Our aim is to elucidate the mechanisms for the pro-tumorigenic effects of TGFb and to develop selective inhibitors which can be used to suppress tumor invasiveness and metastasis in animal models, and later on for treatment of patients with advanced cancer. We think it is important to develop selective inhibitors, which do not affect the tumor suppressive effects of TGFb, since complete inhibition of TGFb may cause severe side effects and may even promote tumorigenesis. We plan to: 1. perform a systematic analysis of posttranslational modifications and interactors of the TGFb receptor I (TbRI) and II (TbRII), and determine their functional importance for the induction of various pro-tumorigenic pathways; 2. determine the mechanism whereby TGFb activates the tyrosine kinase Src, and its role in invasiveness and metastasis; 3. attempt to selectively inhibit the activation of phosphatidylinositol 3´-kinase by TGFb, in order to inhibit tumor cell survival and migration; 4. elucidate the functional role in the nucleus of the cleaved intracellular domain of TbRI, and attempt to inhibit its formation and thereby tumor metastasis; 5. determine the cellular compartment where the pro-tumorigenic signaling pathways are activated; 6. elucidate mechanisms for TGFb-induced EMT and develop candidate low molecular weight inhibitors that we have obtained from a screen, aiming at using them in vivo to suppress metastasis; 7. develop biomarkers to identity patient cohorts for treatment with selective TGFb inhibitors.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores